Categories
Tag: ESGCT
2023-11-07 | NDAQ:VOR | Press Release
Next trem-cel (VOR33) clinical data update expected by Relapse After Transplant and Cellular Therapy (HSCT2) Conference Nov 10-11 Three oral abstracts and two poster presentations accepted at ASH 2023 Dec 9-12 CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company,…
CRISPR gene therapy appears safe, but claims of an imminent HIV cure are premature
A CRISPR-based gene-editing therapy known as EBT-101 was not associated with serious adverse effects in the first three treated study participants, researchers reported last week at the European Society for Gene & Cell Therapy annual meeting in Brussels. The presentation, however, was devoid of any data about whether the treatment…
2023-11-01 | NDAQ:SGMO | Press Release
Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies. Dosed a total of 25 patients in Phase 1/2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional…
Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
– ARCUS showed durable, high-efficiency gene insertion capabilities in NHPs and comparison to CRISPR-Cas9 – Data demonstrates ability of ARCUS to achieve large gene excisions enabling significant functional muscle improvement in a DMD mouse model DURHAM, N.C., October 26, 2023–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company…
Epic Bio Reports New Data on Hypercompact Cas Proteins
– Data being presented at ESGCT reflect improvements upon CasMINI, previously the smallest Cas protein known to work in human cells – – Company’s additional poster presentations report on progress of epigenetic editing platform and lead candidate EPI-321 – SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Epic…
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
Excision BioTherapeutics Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101 No serious adverse events or dose-limiting toxicities were seen in any trial participant EBT-101 was detected in blood in all participants SAN FRANCISCO, Oct. 25, 2023 (GLOBE NEWSWIRE) —…
circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT)
Oslo, Norway, 19 October 2023 – Circio Holding ASA (OSE: CRNA) today announcesthat an abstract describing its circular RNA technology has been accepted forposter presentation at the 30th i European Society for Gene and Cell Therapy inBrussels, Belgium.The poster is scheduled for presentation 25-26 October 2023 and will beavailable on…
Circio: circRNA poster to be presented at the 30th European Society for Gene and Cell Therapy (ESGCT) -October 19, 2023 at 01:05 am EDT
Oslo, Norway, 19 October 2023 – Circio Holding ASA (OSE: CRNA) today announces that an abstract describing its circular RNA technology has been accepted for poster presentation at the 30th iEuropean Society for Gene and Cell Therapy in Brussels, Belgium. The poster is scheduled for presentation 25-26 October 2023 and…
Excision BioTherapeutics Announces Presentation of Interim
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced that interim clinical safety and biodistribution data will be presented at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress, which will…
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…
Voyager Therapeutics Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Voyager Therapeutics, Inc. – Transformational progress in 2022 marked by reprioritization of high-value neurology pipeline and validation of TRACER™ novel capsid platform through transactions with Pfizer and Novartis – – Partnering momentum continues into 2023 with $175 million payment associated with Neurocrine Biosciences strategic collaboration followed by $25 million payment triggered…